Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taking The Higher Moral Ground, Medicines Australia Adopts Tougher Code Of Conduct

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Beginning January 2010, Medicines Australia member companies will need to adhere to a stricter Code of Conduct, which sets the ethical standard for marketing and promotion of prescription medicines in Australia

You may also be interested in...

Watchdog Tells Big Pharma In Australia To Disclose Sponsorship Payments By Early 2015

New rules on sponsorship payment disclosures to start by 2015; Medicines Australia members will begin to disclose aggregate data this year.

Pfizer Grilled By Australia’s TGA Over Payments To Pharmacists

Medicines Australia Calls For Level Playing Field For Ethical Conduct; Govt Not Likely To Intervene

PERTH, Australia - Following recent media reports of pharmaceutical outfits treating doctors to lavish outings, Medicines Australia is calling for a common standard of transparency and accountability for all companies operating in the therapeutics sector in Australia

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts